Biologics have a ceiling. We’re breaking it.
EdiLabs is developing a new way to design, manufacture, and deliver biologics, expanding the frontiers of patient reach and unlocking the next era of biologic innovation.
The global biologics market is set to reach around €600 billion by 2030, but that growth is capped by cost, manufacturing complexity, and injectable delivery. EdiLabs’ edible biologics platform removes those barriers, cutting production costs up to tenfold and enabling biologics to reach 2–3× more patients worldwide.
The Barriers Holding Biologics Back
Biologics have transformed medicine, yet their true potential remains limited by how they’re made, transported, and delivered. These real-world constraints keep prices high, scale low, and access unequal worldwide.
EdiLabs is developing solutions to overcome these long-standing bottlenecks.
Complex and costly to manufacture
Many biologics fail early due to instability, low yields, or high production cost.
Cold-chain dependence
Most require 2–8 °C handling from factory to patient, driving logistics cost and wastage.
Injection-based administration
Delivery through injections and infusions reduces convenience, adherence, and reach.
High cost, low reach
Even proven biologics remain unaffordable for many health systems and patients.
Our Vision for the
Future of Medicine
To transform therapeutic delivery through plant-based biotech innovation, offering accessible, sustainable, and scalable solutions to unmet global health challenges. Our three core pillars are:
Effective Therapeutic Outcomes
Safe & Non‑Invasive Therapies
Affordable & Scalable Manufacturing
